With 30,000 employees and 30+ brands marketed in 175+ countries, AbbVie (NYSE: ABBV) is a global, research-driven biopharmaceutical company developing solutions to complex, critical conditions in therapeutic areas including immunology, oncology, virology and neuroscience (www.abbvie.com). ● Co-developing and leading the global commercial strategy and life cycle planning for MAVIRET chronic hepatitis C treatment with ownership of strategic differentiation, in-field execution of global brand teams, strategic resource allocation, multichannel marketing, performance measurement, and directing course corrections for all countries outside of the US; ● Ensuring optimal positioning by crystalizing commercial and strategic insights through data and analyses of product, brand, customer, and competitive intelligence; ● Identifying key segment value drivers and growth opportunities;● Leading brand enhancement efforts to improve market and share competitiveness, forecasting, enterprise-wide multi-disciplinary collaborations, and strategic mapping with regulatory officials; ● Co-leading long-range financial planning; ● Leading and coaching to foster shared vision/purpose and an accountable, inclusive, inspiring environment that recognizes and facilitates success; ● Representing all GMCO franchises on the In-Field Team Excellence Capability group;● Core member of the Future Fit 2.0 Operating team representing all of Specialty Care with a mandate to strengthen and embed core commercial capabilitiesACHIEVEMENTS: ► Successfully launched a label expansion for MAVIRET (8-week therapy) for treatment-naive HCV patients ► Key member of the team that earned a 2020 AbbVie President's Award for exceptional COVID response across all Global Marketing and Commercial Operations (GMCO)

With 750 employees and $1B invested in R&D since 2000, Merck Canada markets 250+ products in areas including vaccines, virology, cardiology, oncology, biosimilars, acute care hospital, primary care (diabetes, respirology) and infectious diseases (www.merck.ca).● Led all aspects of the Virology business unit including strategic planning, sales, market access, marketing, brand management, customer presence, partnering, pre-launch/launch activities, culture and insights/analytics with full P&L responsibility; ● Managed 5 direct reports, a 14-person sales team and a multi-million dollar budget; ● Grew market share, expanded markets and delivered leveraged P&L by optimizing a focused business model and digital infrastructure, launching innovative programs/offerings and leading deep customer segmentation, tailored account plans/mixes and strong customer partnerships;● Led an initiative in Canada’s BC province: a cross functional leadership role with oversight of all Merck portfolio, policy, market access, and medical teams with a mandate to deliver incremental sales and P&L performance;● Served as Therapy Area leader for the commercialization of Virology products and linking science to patient and commercial opportunities; ● Directed talent strategy, hiring and training and established and measured performance targets; ● Collaborated as a key member of the national leadership team in defining vision, organizational development, growth planning and increasing brand value. ACHIEVEMENTS: ► Delivered breakthrough performance and exceeded targets for sales, market share and HCV patient cures for ZEPATIER® ► Significantly grew ISENTRESS® NRx in a highly competitive market ► Developed a strategy to launch a significant, multi-product HIV portfolio in Canada ► Achieved impact with indigenous communities by implementing educational partnerships and Total Population Health initiatives

● Oversaw a 50-employee Canadian Hospital & Specialty Business Unit that encompassed 15 products and three portfolios (Acute Care Hospital, Virology and Fertility); ● Led national sales and marketing, market access, pricing and reimbursement and CME programs; ● Managed 7 direct reports and a 35-person sales team; ● Established the business unit’s strategic agenda and direction and led the execution of business/product plans and growth strategies through all lifecycle stages in diverse clinical settings; ● Directed talent acquisition, development, account management and go-to-market models; ● Following an $8.4B acquisition, managed the integration of Cubist Pharmaceuticals’ products (ZERBAXA®,DIFICID®, SIVEXTRO®), staff, processes and systems into Merck’s Canadian Hospital & Specialty Business Unit in 2015 and 2016; ● Established a leadership development program to accelerate the development of high potential team members.ACHIEVEMENTS: ► Delivered leveraged P&L ► Significantly increased sales by building a new go-to-market model and organizational structure that allowed the business unit and product portfolio to adapt/align to, and capitalize on, a complex hospital system and diversity nationwide ► Returned the Fertility portfolio business back to growth in 2016, achieved #1 ranked growth and percentage to plan globally, and profitably increased YOY sales ► Led the launch of ZERBAXA® to exceed sales targets in a slow uptake market ►Achieved 90% formulary listing of BRIDION® in Top 50 accounts and full reimbursement in 8 of 10 provinces ► Realized best-in-globe growth for POSANOL® after 8 years on the market ► Established an Antimicrobial Resistance partnership with the Canadian Institute of Health Research and collaborated with scientific leaders, researchers, government and policy makers to create a Canadian strategy and framework for action ► Chosen for the HELIOS Leadership Development program in 2017

● Oversaw a 55-employee business unit that marketed private/public pediatric, adolescent and adult vaccines to general practitioners and pharmacies (retail and hospital); ● Led national sales and marketing, channel management, policy and access with P&L responsibility; ● Managed a 40-person sales force; ● Led the development and execution of a company-wide Culture Plan that improved engagement and customer focus;● Contributed as a key member of the Canadian leadership team and represented Merck on the Vaccine Industry Committee (January 2012 to March 2014). ACHIEVEMENTS: ► Delivered a leveraged P&L from 2012 through 2013 while optimizing the vaccine portfolio to deliver 50% growth ► Doubled sales of ZOSTAVAX® and increased sales of GARDASIL® ► Generated significant incremental revenue by expanding an inline portfolio of 7 pediatric, adolescent and adult vaccines via negotiating pricing and competing in tenders against key competitors ► Led negotiation and partnering with provinces to launch shingles immunization programs in Ontario and successfully integrated shingles immunization into the Ministry of Health’s Seniors Strategy and Health Economics Outcomes Research for Public Health Ontario ► Leveraged extensive DTC campaign experience and developed/directed an innovative federal HPV vaccine tender (price/volume) and partnership with the province of Alberta to expand female-only vaccination programs to include males

In November 2009, Merck merged with Schering-Plough in a $41B deal in which the latter was renamed Merck & Co., Inc. By end of 2013, the company was one of the world's seven largest pharmaceutical companies with approx 76,000 employees in 120 countries and 31 factories worldwide (www.merck.com).● Co-led the 9-figure revenue USD Vaccines franchise business in the Asia Pacific region across 10 markets (India, Vietnam, Indonesia, Korea, Taiwan, Malaysia, Singapore, Hong Kong, Philippines and Thailand); ● Managed commercial execution, supply and the implementation of marketing plans and all product strategy and related communications for 10 brands; ● Directed collaborations with country and region-specific partners; ● Developed business cases, business plans and financial forecasts; ● Established compliance standards and programs; ● Drove product line performance, specification and quality improvement initiatives; ● Cultivated KOLs, product advocates and speakers; ● Assisted in shaping public relations and economics strategy;● Served as Acting Head of the Vaccines Business Unit Head in Taiwan for six months and was directly involved in negotiating with local governments to secure public access for GARDASIL® in 8 communities. ACHIEVEMENTS: ► Led turnaround by planning, implementing and supporting change in India, Hong Kong, Taiwan, Malaysia, Philippines and Thailand that improved business growth from double digit negative in 2010 to double digit positive (2011 vs. 2010) through market research in 5 countries, targeted insight-driven marketing, customer profiling, improved performance tracking/metrics, strategic messaging and promotional resources, customer visits, and 1:1/team meetings with country leaders ► Led growth in new launch and older indications by delivering more upside to emerging markets ► Delivered significant growth in Korea for adult women through corporate immunization programs and partnerships with Korean Air and Samsung

● Strengthened Vaccine teams, strategies, capabilities and competencies across the Japan organization (Medical, Public Health & Policy, Sales and Marketing Excellence); ● Recruited and mentored 5 product managers to drive national franchising, share, revenue, adoption and branding; ● Led launch planning and cross-functional teams. ACHIEVEMENTS: ► Led an innovative pre-launch plan for GARDASIL® the most successful in the world) ► Achieved +200% growth for PNEUMOVAX® via an innovative sub-national policy strategy that resulted in 100+ local reimbursements and a DTC campaign that generated rapid uptake and second best sales levels globally ► In collaboration with the Japan Executive Committee and Business Development Lead, led the development of MSD Japan-generic entry strategy and lifecycle management planning that was identified as 1 of 5 top growth priorities for MSD Japan

A Canadian affiliate of Merck & Co, Merck Frosst was an integrated pharmaceutical company with operations that included the largest biomedical research facility in Canada (35-acres) which closed in 2010 after a global merger with Schering-Plough in 2009. ● Managed the best-in-globe launch and national marketing for GARDASIL® that delivered leading results among international peers across all product life cycles; ● Led brand team and task force; ● Planned and led marketing and CME events. ACHIEVEMENTS: ► Earned a Director’s Award, an International Special Events Society (ISES) Award, and a Canadian Healthcare Marketing Hall of Fame Award in 2006 for the successful launch of GARDASIL® in Canada and DTC "Tell Someone" HPV awareness campaign

● Developed the marketing plan for ROTATEQ®and led the brand team through the execution of the pre-launch plan phase in Canada.

● Managed 8-12 Sales Trainers and led overall coaching and training of field sales force;● Led design, development and execution of field selling skills training programs including communication skills, territory planning, sales manager training, etc.;● Represented the department on marketing teams.ACHIEVEMENTS: ► Earned Director's Award for excellence in 2004